http://rdf.ncbi.nlm.nih.gov/pubchem/reference/29441964

Outgoing Links

Predicate Object
contentType Clinical Trial|Clinical Trial, Phase I|Comparative Study|Journal Article|Multicenter Study
endingPage 54
issn 1523-5866
1522-8517
issueIdentifier 1
pageRange 44-54
publicationName Neuro-Oncology
startingPage 44
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_5a0eb2fadabf1dffb4d70280b760adba
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_ceb53bbea8a0aa89b06d224fd2f722be
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_5a26b50287387e53f7f59d10824810a2
bibliographicCitation Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL, Hess KR, Kuhn J; North American Brain Tumor Consortium study. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2004 Jan;6(1):44–54. PMID: 14769140; PMCID: PMC1871968.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c25717dabb7a318d947541002d7c9bb3
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4b03e2b43eab69fae5a3ade63480b4e5
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_515ff969a139d291b27eae6ffb93c548
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f052643c51f7e70430e9801bc346409c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_85e05febe80244264dfb026f17b3cffd
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bb216cdaab2bd2780d3ac29ddcbddbd6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_54411333136ec254830964124b17d9be
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_75762f8ee54335e659eb9482738c4c39
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a564255d79e89c405813651b9bfa5e15
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_46a0ee4273b39b323868d7061a9c34be
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ddbd3868aa0cffaf6c43ea047f85eeff
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1656f05a7c94bc84562389e337883ead
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b6ef6c0e3138ccbc7e51ec15a875e373
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_132853a198f2c03805c00b88727361a1
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c12f17dfe1426a73f5cbe82e5cf42424
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0c54610afdd1d148c27d2fccd7e04ae8
date 2004-01-01^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1215/s1152851703000292
https://pubmed.ncbi.nlm.nih.gov/PMC1871968
https://pubmed.ncbi.nlm.nih.gov/14769140
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21645
https://portal.issn.org/resource/ISSN/1523-5866
https://portal.issn.org/resource/ISSN/1522-8517
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study
discusses http://id.nlm.nih.gov/mesh/M0147530
http://id.nlm.nih.gov/mesh/M0001486
http://id.nlm.nih.gov/mesh/M0003242
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D002166Q000031
http://id.nlm.nih.gov/mesh/D002166Q000008
http://id.nlm.nih.gov/mesh/D000972Q000008
http://id.nlm.nih.gov/mesh/D005910Q000188
http://id.nlm.nih.gov/mesh/D009364Q000188
http://id.nlm.nih.gov/mesh/D001932Q000188
hasSubjectTerm http://id.nlm.nih.gov/mesh/D009364Q000097
http://id.nlm.nih.gov/mesh/D001932Q000097
http://id.nlm.nih.gov/mesh/D000328
http://id.nlm.nih.gov/mesh/D016014
http://id.nlm.nih.gov/mesh/D004305
http://id.nlm.nih.gov/mesh/D000077146
http://id.nlm.nih.gov/mesh/D005910Q000097
http://id.nlm.nih.gov/mesh/D000972Q000493
http://id.nlm.nih.gov/mesh/D002166Q000493
http://id.nlm.nih.gov/mesh/D019540
http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D000368
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D000972Q000009
http://id.nlm.nih.gov/mesh/D002166Q000009
http://id.nlm.nih.gov/mesh/D009656
http://id.nlm.nih.gov/mesh/D018709
http://id.nlm.nih.gov/mesh/D008875
http://id.nlm.nih.gov/mesh/D005260
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID129675524
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID74990
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60838
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60837
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID104842
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7099
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID443154
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3955
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID156963281
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7839

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129113875
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129520161
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129430288

Showing number of triples: 1 to 83 of 83.